United Therapeutics (UTHR) Invested Capital (2016 - 2025)
Historic Invested Capital for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $6.6 billion.
- United Therapeutics' Invested Capital rose 137.37% to $6.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 billion, marking a year-over-year increase of 137.37%. This contributed to the annual value of $6.7 billion for FY2024, which is 562.59% up from last year.
- Per United Therapeutics' latest filing, its Invested Capital stood at $6.6 billion for Q3 2025, which was up 137.37% from $7.2 billion recorded in Q2 2025.
- United Therapeutics' 5-year Invested Capital high stood at $7.2 billion for Q2 2025, and its period low was $3.4 billion during Q1 2021.
- In the last 5 years, United Therapeutics' Invested Capital had a median value of $5.4 billion in 2023 and averaged $5.3 billion.
- Its Invested Capital has fluctuated over the past 5 years, first surged by 3310.82% in 2023, then soared by 137.37% in 2025.
- Quarter analysis of 5 years shows United Therapeutics' Invested Capital stood at $4.0 billion in 2021, then rose by 21.16% to $4.8 billion in 2022, then skyrocketed by 33.11% to $6.4 billion in 2023, then increased by 5.63% to $6.7 billion in 2024, then decreased by 2.28% to $6.6 billion in 2025.
- Its Invested Capital was $6.6 billion in Q3 2025, compared to $7.2 billion in Q2 2025 and $7.0 billion in Q1 2025.